Cleary M L, Meeker T C, Levy S, Lee E, Trela M, Sklar J, Levy R
Cell. 1986 Jan 17;44(1):97-106. doi: 10.1016/0092-8674(86)90488-5.
Following treatment of a human B cell lymphoma with an anti-idiotype antibody, a subpopulation of tumor cells remained that had lost the tumor-specific heavy chain idiotypic determinant. Nucleotide sequence analyses of eight independent heavy chain variable region isolates showed extensive point mutations, so that no two sequences were identical. Comparison of pretreatment and posttreatment sequences implicated an amino acid in CDR2 as being involved in the idiotypic determinant. Apparently the malignant B cells escaped the therapeutic effects of the anti-idiotype antibody through an ongoing process of somatic mutation in their immunoglobulin genes. Non-random clustering of amino acid replacements in CDR2 suggested that growth of the tumor may have been influenced by endogenous selective forces interacting with the tumor cell-surface immunoglobulin.
用抗独特型抗体治疗人类B细胞淋巴瘤后,仍有一部分肿瘤细胞亚群丢失了肿瘤特异性重链独特型决定簇。对八个独立的重链可变区分离株进行的核苷酸序列分析显示存在广泛的点突变,因此没有两个序列是相同的。治疗前和治疗后序列的比较表明,互补决定区2(CDR2)中的一个氨基酸与独特型决定簇有关。显然,恶性B细胞通过其免疫球蛋白基因中持续的体细胞突变过程逃避了抗独特型抗体的治疗作用。CDR2中氨基酸替换的非随机聚类表明,肿瘤的生长可能受到与肿瘤细胞表面免疫球蛋白相互作用的内源性选择力的影响。